Amphiphilic Imidazolinium Synthesis Without BOC Protecting Groups
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for preparing amphiphilic imidazolinium compounds like DOTIM are costly, toxic, and generate significant waste due to the use of tert-butyloxycarbonyl (BOC) protecting groups and the need for expensive reagents such as di-tert-butyl dicarbonate and triethylamine, with labor-intensive purification processes.
Innovation Solution
A process that avoids BOC protecting groups and the use of bases during acylation, using hydrogen halides and carboxylic acid halides or anhydrides to synthesize amphiphilic imidazolinium compounds, reducing waste and costs, and incorporating a rearrangement reaction to form the imidazolinium compound.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If BOC protecting groups and di-tert-butyl dicarbonate are used to protect secondary amines during acylation, then selective acylation of primary hydroxyl groups is achieved, but process cost increases and toxic waste is generated
Solution Approach 1:
The invention extracts and removes the harmful BOC protecting group system from the synthesis pathway. By using a alternative approach that forms the imidazolinium ring directly during acylation, the process eliminates di-tert-butyl dicarbonate and the toxic waste it generates, while still achieving selective acylation of the primary hydroxyl group.
Solution Approach 2:
Instead of protecting the secondary amine first and then acylating, the invention inverts the sequence by forming the imidazolinium ring structure during the acylation step itself. This reversal eliminates the need for protecting groups while maintaining selectivity through the unique reactivity of the system.
2Manufacturing precision
If BOC protecting groups are used and removed by acid hydrolysis, then amine protection is achieved, but additional organic and aqueous waste is generated
Solution Approach 1:
The invention extracts the problematic protection-deprotection sequence from the synthesis pathway. By forming the imidazolinium ring directly during acylation without requiring subsequent acid hydrolysis, the process eliminates the generation of additional organic and aqueous waste that would result from removing BOC groups.
Solution Approach 2:
The invention creates a continuous process where acylation and ring formation occur in a single step without interruption for protection or deprotection. This eliminates the intermediate steps that would generate waste streams, making the process more efficient and environmentally friendly.
3Ease of manufacture
If acid halides with base (triethylamine) or DCC/DMAP are used for acylation, then ester formation is achieved, but process cost increases and labor-intensive purification is required
Solution Approach 1:
The invention extracts and removes the problematic reagents (triethylamine, DCC, DMAP) from the acylation process. By using a different mechanism that forms the imidazolinium ring during acylation, the process eliminates the need for these reagents and the labor-intensive purification steps required to remove their byproducts.
Solution Approach 2:
The invention enables the reaction system to perform its own purification function. The imidazolinium salt product precipitates directly from the reaction mixture in a clean form that requires minimal purification, eliminating the need for extensive chromatography or recrystallization steps that would be required with traditional methods.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process yields highly pure amphiphilic imidazolinium compounds efficiently, with higher yields and reduced environmental impact, making it scalable and cost-effective while maintaining high product purity.
Implementation Method 1
heating the compound of Formula (IV) to provide the compound of Formula (I)
Data Source
AI summary
The present invention generally relates to improved processes for the preparation of amphiphilic imidazolinium compounds such as 1-[2-(9(Z)-octadecenoyloxy)ethy1]-2-(8(Z)-heptadecenyl)-3-(2-hydroxyethyl)imidazolinium chloride (DOTIM). In particular, the invention relates to processes for the synthesis of such compounds that avoid the need for toxic reagents, are more economical, and result in less waste than conventional methods. DOTIM and similar compounds can be formulated as cationic liposomes, which are useful as chemical vectors for nucleic acid delivery in gene therapy.